Abstract:OBJECTIVE Lung cancer is the leading cause of cancer death worldwide.Epidermal growth factor receptor(EGFR)mutation(s)is/are common in non-small cell lung cancer(NSCLC)in Asian population,resulting in lung tumor formation.L858 Rsubstitution mutation on exon 21 and in-flame deletion mutation on exon 19 are the two most common forms of EGFR mutation.Molecular targeted therapy using tyrosine kinase inhibitor(TKI)targeting EGFR shows promising initial response,however drug resistance is common.Therefore,it is needed to identify new inhibitors to tackle TKI-resistance.In this study,we aim to investigate the effect of multiple single purified compounds derived from Chinese herbal medicines(CMHs)on a panel of NSCLC cell lines with different EGFR mutational statuses and TKI sensitivity.We also examine the biological functional effect and drug action mechanism of these cell lines after drug treatment.METHODS We have reviewed the literature and selected ten single purified compounds derived from CMHs which exhibited the highest potential of cancer suppression effect in NSCLC.We have recruited three EGFR-dependent NSCLC cell lines for drug screening using cytotoxicity assay.A549 is used as EGFR wild-type control.Two TKI-resistant NSCLC cell lines were used,H1975 harbors double mutation(EGFRL858R+T790M)and H1650 harbors EGFRexon 19 deletion.H2228is a NSCLC cell line which harbours EML4-ALK fusion gene and was used as EGFR-independent cell line control.MTT assay was used to determine the drug efficacy and IC50 value.Then functional assays including cell cycle arrest analysis and apoptosis assay was used to determine the biological effect after drug treatment.RESULTS MTT assay revealed that six out of ten candidate agents showed significant cancer-inhibiting effects in H1650 and H1975cells.Three compounds exhibited IC50 value at micro-molar levels while another three compounds exhibited IC50 at as low as nano-molar levels.One compound exhibited specificity on EGFR-dependent NSCLC cell lines,which showed 10-fold more selective

Research Progress of Traditional Chinese Medicine Inhibition of NSCLC Acquired Drugs Resistance to EGFR-TKI

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Research progress on the mechanism of acquired drug resistance of epi-dermal growth factor receptor tyrosine kinase inhibitor and reversal in traditional Chinese medicine

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Progress of Chinese Medicine Monomers and Combinations in Intervening Gefitinib Resistance in Non-small Cell Lung Cancer

[Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer].

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

Mechanism and Treatment Associated with Resistance to EGFR-TKI

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

Research progress of the mechanisms on the drug-resistance of EGFR-TKIs in non-small cell lung cancer

Clinical Progress for the EGFR-TKI Combined with Radiotherapy in Non-Small Cell Lung Cancer

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

Recent progress in targeted therapy for non-small cell lung cancer

The Treatment of EGFR-TKI Resistance in Non-small Cell Lung Cancer

Specific Growth Inhibition by Alteration of Metabolic Pathway Using Chinese Herbal Medicine in Tyrosine Kinase Inhibitor Resistant Non-Small Cell Lung Cancer

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy